In 2017, Damon Runyon scientists paved the way for new approaches to cancer prevention and cures through innovative research cutting across the most promising areas of cancer research.

**THIS YEAR, FOR EXAMPLE, DAMON RUNYON SCIENTISTS**

- Pioneered the development of CAR-T cell immunotherapies, two of which were approved by the FDA this year.
- Engineered a new therapy to target neuroblastoma, a cancer affecting infants and young children.
- Conducted one of the first clinical trials of personalized cancer vaccines.
- Identified at the molecular level why immunotherapy works only in some patients, leading the way to next-generation therapies.
- Developed a system to identify new “druggable” targets in cancers that lack effective treatments.

**AWARDS AND HONORS RECEIVED BY DAMON RUNYON ALUMNI**

**Elections to the National Academies of Science and Medicine** (the science “Halls of Fame”): Scott A. Armstrong, MD, PhD (Dana-Farber Cancer Institute); Howard Y. Chang, MD, PhD (Stanford University); Rachel Green, PhD (Johns Hopkins University School of Medicine); Michael E. Greenberg, PhD (Harvard Medical School); and Ardem Patapoutian, PhD (Scripps Research Institute).

**Former Innovator Feng Zhang, PhD**, received the Albany Medical Center Prize in Medicine and Biomedical Research for his role in the creation of the CRISPR-Cas9 gene editing system that has been called the “discovery of the century.”

**Current Board Member and former Fellow Elaine V. Fuchs, PhD**, received the 2017 McEwen Award for Innovation, recognizing groundbreaking work in stem cells or regenerative medicine.

**Former Fellow Pardis C. Sabeti, MD, PhD**, received the Richard Lounsbery Award from the National Academy of Sciences for her pioneering work on genetic evolution, and leadership in global efforts to increase data sharing in pandemics, including Ebola and Lassa Fever.

**Former Fellow Daniel E. Webster, PhD**, was named a 2017 STAT Wunderkind for his development of an app that allows people at risk of skin cancer to track their moles and share data with researchers and clinicians.
OUR MISSION

To accelerate breakthroughs, the Damon Runyon Cancer Research Foundation provides today’s best young scientists with funding to pursue innovative cancer research.

RESEARCH PROGRAMS

- We are currently funding 189 researchers at 52 institutions across the nation.
- In fiscal 2017, we awarded $17 million in new grants to 63 exceptional scientists in nine states.

FINANCIAL INFORMATION

Revenue: $20.8 Million
- Investment Return 46.4%
- Contributions 44.0%
- Misc. Income 4.1%
- Damon Runyon Broadway Tickets 3.1%
- Bequests & Trusts 2.4%

Expenses: $20.8 Million
- Award Programs 82.7%
- Fundraising 14.7%
- General Administration 2.6%

100% of donations fund cancer research.

Our low administrative costs are paid from Damon Runyon Broadway Tickets and our endowment.

DISCOVERING THE TALENT TO DISCOVER THE CURE

www.DamonRunyon.org
1.877.7CANCER